Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

Authors Jain MD, Bachmeier CA, Phuoc VH, Chavez JC

Received 11 February 2018

Accepted for publication 3 April 2018

Published 31 May 2018 Volume 2018:14 Pages 1007—1017

DOI https://doi.org/10.2147/TCRM.S145039

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh


Michael D Jain,1,2 Christina A Bachmeier,3 Vania H Phuoc,2 Julio C Chavez,2,4

1Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA; 2Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA; 3Department of Pharmacy, Moffitt Cancer Center, Tampa, FL, USA; 4Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA

Abstract: Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercially approved by the US Food and Drug Administration for relapsed or refractory aggressive non-Hodgkin’s lymphomas including diffuse large B-cell lymphoma and its variants. The ZUMA-1 Phase I and II clinical trials formed the basis of the US Food and Drug Administration approval of this product, and we discuss the particulars of the clinical trials and the pharmacology of axi-cel. In addition, we review the CD19 chimeric antigen receptor T-specific toxicities of cytokine release syndrome and neurotoxicity, which remain the challenges to the safe delivery of this important therapy for aggressive B-cell lymphomas with poor prognosis.

Keywords: axicabtagene ciloleucel, CAR T, non-Hodgkin’s lymphoma, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]